> top > docs > PubMed:32418114 > annotations

PubMed:32418114 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T1 12-30 CHEBI:5801;DG_20;CHEBI:5801 denotes hydroxychloroquine
T2 80-88 SP_7 denotes COVID-19
T3 90-101 NCBITaxon:11118 denotes Coronavirus
T4 116-124 SP_7 denotes COVID-19
T5 157-162 CHEBI:23888;CHEBI:23888 denotes drugs
T6 267-285 CHEBI:5801;DG_20;CHEBI:5801 denotes hydroxychloroquine
T7 319-324 GO:0016265 denotes death
T8 348-356 SP_7 denotes COVID-19
T9 427-435 SP_7 denotes COVID-19
T10 608-617 CHEBI:35718;CHEBI:35718 denotes antiviral
T11 618-623 CHEBI:36044;CHEBI:36044 denotes drugs
T12 628-639 CHEBI:33282;CHEBI:33282 denotes antibiotics
T13 674-678 UBERON:0000165 denotes oral
T14 874-892 CHEBI:5801;DG_20;CHEBI:5801 denotes hydroxychloroquine
T15 1088-1093 GO:0016265 denotes death
T16 1219-1223 PR:000001393 denotes IL-6
T17 1587-1595 SP_7 denotes COVID-19
T18 1726-1734 SP_7 denotes COVID-19
T19 1784-1802 CHEBI:5801;DG_20;CHEBI:5801 denotes hydroxychloroquine
T20 1804-1808 PR:000001393 denotes IL-6
T21 1823-1831 SP_7 denotes COVID-19

hydroxychloroquine

Id Subject Object Predicate Lexical cue hp_id
T1 1632-1646 Phenotype denotes cytokine storm http://purl.obolibrary.org/obo/HP_0033041

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-89 Sentence denotes Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.
T2 90-181 Sentence denotes Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high fatality.
T3 182-235 Sentence denotes The most urgent need is to find effective treatments.
T4 236-366 Sentence denotes We sought to determine whether hydroxychloroquine (HCQ) application may reduce the death risk of critically ill COVID-19 patients.
T5 367-543 Sentence denotes In this retrospective study, we included 550 critically ill COVID-19 patients who need mechanical ventilation in Tongji Hospital, Wuhan, from February 1, 2020 to April 4, 2020.
T6 544-764 Sentence denotes All 550 patients received comparable basic treatments including antiviral drugs and antibiotics, and 48 of them were treated with oral HCQ treatment (200 mg twice a day for 7-10 days) in addition to the basic treatments.
T7 765-911 Sentence denotes Primary endpoint is fatality of patients, and inflammatory cytokine levels were compared between HCQ and non-hydroxychloroquine (NHCQ) treatments.
T8 912-1046 Sentence denotes We found that fatalities are 18.8% (9/48) in HCQ group, which is significantly lower than 47.4% (238/502) in the NHCQ group (P<0.001).
T9 1047-1182 Sentence denotes The time of hospital stay before patient death is 15 (10-21) days and 8 (4-14) days for the HCQ and NHCQ groups, respectively (P<0.05).
T10 1183-1436 Sentence denotes The levels of inflammatory cytokine IL-6 were significantly reduced from 22.2 (8.3-118.9) pg mL-1 at the beginning of the treatment to 5.2 (3.0-23.4) pg mL-1 (P<0.05) at the end of the treatment in the HCQ group but there is no change in the NHCQ group.
T11 1437-1647 Sentence denotes These data demonstrate that addition of HCQ on top of the basic treatments is highly effective in reducing the fatality of critically ill patients of COVID-19 through attenuation of inflammatory cytokine storm.
T12 1648-1832 Sentence denotes Therefore, HCQ should be prescribed as a part of treatment for critically ill COVID-19 patients, with possible outcome of saving lives. hydroxychloroquine, IL-6, mortalities, COVID-19.
T1 0-89 Sentence denotes Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19.
T2 90-181 Sentence denotes Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high fatality.
T3 182-235 Sentence denotes The most urgent need is to find effective treatments.
T4 236-366 Sentence denotes We sought to determine whether hydroxychloroquine (HCQ) application may reduce the death risk of critically ill COVID-19 patients.
T5 367-543 Sentence denotes In this retrospective study, we included 550 critically ill COVID-19 patients who need mechanical ventilation in Tongji Hospital, Wuhan, from February 1, 2020 to April 4, 2020.
T6 544-764 Sentence denotes All 550 patients received comparable basic treatments including antiviral drugs and antibiotics, and 48 of them were treated with oral HCQ treatment (200 mg twice a day for 7-10 days) in addition to the basic treatments.
T7 765-911 Sentence denotes Primary endpoint is fatality of patients, and inflammatory cytokine levels were compared between HCQ and non-hydroxychloroquine (NHCQ) treatments.
T8 912-1046 Sentence denotes We found that fatalities are 18.8% (9/48) in HCQ group, which is significantly lower than 47.4% (238/502) in the NHCQ group (P<0.001).
T9 1047-1182 Sentence denotes The time of hospital stay before patient death is 15 (10-21) days and 8 (4-14) days for the HCQ and NHCQ groups, respectively (P<0.05).
T10 1183-1436 Sentence denotes The levels of inflammatory cytokine IL-6 were significantly reduced from 22.2 (8.3-118.9) pg mL-1 at the beginning of the treatment to 5.2 (3.0-23.4) pg mL-1 (P<0.05) at the end of the treatment in the HCQ group but there is no change in the NHCQ group.
T11 1437-1647 Sentence denotes These data demonstrate that addition of HCQ on top of the basic treatments is highly effective in reducing the fatality of critically ill patients of COVID-19 through attenuation of inflammatory cytokine storm.
T12 1648-1832 Sentence denotes Therefore, HCQ should be prescribed as a part of treatment for critically ill COVID-19 patients, with possible outcome of saving lives. hydroxychloroquine, IL-6, mortalities, COVID-19.